Frazier Healthcare V

Frazier Healthcare V, established in 1991, is a Seattle-based private equity firm with a focus on the healthcare sector. With over $2 billion under management, the firm invests in growth capital for healthcare companies, spanning from venture capital to growth buyouts. Frazier Healthcare V primarily invests in life science, healthcare devices and supplies, pharmaceuticals, and biotechnology sectors, demonstrating a commitment to innovation and unmet medical needs. The firm takes an active approach to portfolio management, leveraging its deep domain expertise and extensive network of industry thought leaders.

Steve Bailey

Partner and CFO

Kent Berkley

Partner

Clarissa Berman

Vice President

Jamie Brush

Senior Associate

James Brush

General Partner and Portfolio Manager

Joe Cabral

Principal

Murphy "Andy" Caine

Partner and COO of CoE

Albert Cha

Managing Partner

James D'Onofrio

Senior Associate

Anthony Draye

CoE - Partner, Technology and Innovation

Nathan Every

General Partner

Daniel Ewnetu

Associate

Volodymyr Gulidov

Associate

Anna Hamm

Associate

Tanya Hayes

CoE - Partner, Human Capital and ESG

Matt Hinshaw

Vice President

Matthew Hinshaw

Vice President

Jeremy Janson

Principal

Aditya Kohli

Venture Partner

Kevin Li

Principal

Ryan Lucero

Partner

Michael Machak

Senior Associate

Ben Magnano

Managing Partner

Angel Martin Ph.D

Senior Associate

Nader J. Naini

Managing Partner

Luke Ostrander

Associate

Christina Miller Reszka

Partner

Jack Stephenson

Associate

Shyamal Swami

Principal

Steven Tallman

Operating Partner

James Topper

General Partner

Jack Trunzo

Vice President

Joe Whitters

Executive Partner

Andrew Wu

Senior Associate

Eric Yang

Associate

Jennifer Zhuang

Senior Associate

Past deals in Macau

SanReno Therapeutics

Funding Round in 2021
SanReno Therapeutics specializes in the development, manufacturing, and commercialization of therapies for kidney diseases in several regions including the People's Republic of China, Hong Kong, Macau, Taiwan, and Singapore. Established through a joint venture involving Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, the company is dedicated to researching and producing innovative biotech solutions aimed at improving the quality of life for patients suffering from kidney-related conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.